Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSemak, Vladislav-
dc.contributor.authorSemakova, Jana-
dc.contributor.authorHalbaut, Lyda-
dc.contributor.authorAso Pérez, Ester-
dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)-
dc.contributor.authorCalpena Campmany, Ana Cristina-
dc.contributor.authorEscolano Mirón, Carmen-
dc.contributor.authorPerales Losa, Carlos-
dc.description.abstractTriheptanoin-enriched diets have been successfully used in the experimental treatment of various metabolic disorders. Maximal therapeutic effect is achieved in the context of a ketogenic diet where triheptanoin oil provides 30-40% of the daily caloric intake. However, pre-clinical studies using triheptanoin-rich diets are hindered by the difficulty of administering to laboratory animals as a solid foodstuff. In the present study, we successfully synthesized triheptanoin to the highest standards of purity from glycerol and heptanoic acid, using sulfonated charcoal as a catalyst. Triheptanoin oil was then formulated as a solid, stable and palatable preparation using a ketogenic base and a combination of four commercially available formulation agents: hydrophilic fumed silica, hydrophobic fumed silica, microcrystalline cellulose, and talc. Diet compliance and safety was tested on C57Bl/6 mice over a 15-week period, comparing overall status and body weight change. Practical applications: This work provides a complete description of (i) an efficient and cost-effective synthesis of triheptanoin and (ii) its formulation as a solid, stable, and palatable ketogenic diet (triheptanoin-rich; 39% of the caloric intake) for rodents. Triheptanoin-rich diets will be helpful on pre-clinical experiments testing the therapeutic efficacy of triheptanoin in different rodent models of human diseases. In addition, using the same solidification procedure, other oils could be incorporated into rodent ketogenic diet to study their dosage and long-term effects on mammal health and development. This approach could be extremely valuable as ketogenic diet is widely used clinically for epilepsy treatment.-
dc.format.extent7 p.-
dc.relation.isformatofVersió preprint del document publicat a:
dc.relation.ispartofEuropean Journal of Lipid Science and Technology, 2012, vol. 114, num. 8, p. 889-895-
dc.rights(c) Wiley-VCH, 2012-
dc.subject.classificationSíntesi orgànica-
dc.subject.otherOrganic synthesis-
dc.titleSynthesis of triheptanoin and formulation as a solid diet for rodentseng
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Institut de Biomedicina (IBUB))
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
605838.pdf246.1 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.